The recent revision in terminology, with noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) replacing noninvasive follicular variant of papillary thyroid carcinoma, has reclassified the clinically indolent tumor as nonmalignant. The objective of this study was to evaluate the impact of this change on the rate of malignancy (ROM) for subcategories of an atypia of undetermined significance (AUS) diagnosis on fine-needle aspiration (FNA) cytology. METHODS: Consecutive thyroid FNAs interpreted as AUS over a period of 4 years were retrospectively analyzed. The ROM for AUS subcategories, including atypia of undetermined significance with nuclear atypia (AUS-N), atypia of undetermined significance with a microfollicular pattern (AUS-F), atypia of undetermined significance with nuclear atypia and a microfollicular pattern (AUS-N/F), atypia of undetermined significance with H€ urthle cells (AUS-H), and atypia of undetermined significance, not otherwise specified (AUS-NOS), were analyzed. RESULTS: Of the 426 nodules interpreted as AUS, 244 were surgically excised. The incidence of NIFTP in each subcategory was as follows: 18% for AUS-N, 18% for AUS-F, 9% for AUS-N/F, 3% for AUS-H, and 0% for AUS-NOS. After the reclassification of NIFTP as nonmalignant, the ROM based on histologic follow-up significantly decreased from 43% to 26% for AUS-N (P < .001) and from 29% to 10% for AUS-F (P 5 .008). The ROM for AUS-N remained significantly higher than the ROM for AUS-F (P 5 .030). CONCLUSIONS: A subset of resected AUS nodules can be reclassified as NIFTP, and that significantly decreases the ROM, especially for AUS-N and AUS-F. Nonetheless, AUS-N still harbors a substantially higher ROM than AUS-F.
INTRODUCTION
Atypia of undetermined significance (AUS) as an indeterminate diagnostic category was introduced by The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) in 2010. 1 This category is reserved for fineneedle aspiration (FNA) in which there is cellular and/or architectural atypia, but the atypia is insufficient to qualify as suspicious. AUS has been reported in 3% to 27% of all thyroid FNAs with a rate of malignancy (ROM) ranging from 6% to 33%. [2] [3] [4] [5] [6] [7] TBSRTC has illustrated several scenarios for the diagnosis of AUS, and this highlights the heterogeneous nature of this category. 1 Previous studies have demonstrated that subcategorizing AUS nodules on the basis of features such as nuclear atypia, a microfollicular pattern, and H€ urthle cell predominance yields significant differences in the ROM on followup. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] An editorial review has shown that atypia of undetermined significance with nuclear atypia (AUS-N) has the highest ROM on resection (55%), and it is followed by atypia of undetermined significance, not otherwise specified (AUS-NOS; 35%), atypia of undetermined significance with a microfollicular pattern (AUS-F; 22%), and atypia of undetermined significance with H€ urthle cells (AUS-H; 6%). 22 Accordingly, the recently published 2017 TBSRTC recommends further subcategorization of an AUS diagnosis. 23 Two recent developments are making a substantial impact on diagnostic practices related to thyroid cytopathology. First, molecular testing is increasingly being applied to indeterminate thyroid nodules to inform therapeutic decisions, particularly the need for surgical resection. 24 Most notably, the Afirma gene expression classifier (GEC) is widely used at many diagnostic centers to recognize benign nodules and thus reduce overtreatment of the harmless indeterminate nodule. Second, a recent revision in thyroid tumor nomenclature has repositioned a subset of thyroid neoplasms from a malignant category to a nonmalignant one. Noninvasive forms of follicular variant of papillary thyroid carcinoma (FVPTC) without worrisome histologic features are now designated as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). 25 This revision significantly decreases the ROM for resected AUS nodules by 2.3% to 17.6%. [26] [27] [28] [29] [30] Only a few studies on the ROM for AUS subcategories have considered these recent changes. 17, 18, 21 The objective of this current study was to evaluate the impact of NIFTP on the ROM across all AUS subcategories at a tertiary care center that routinely applies the GEC for indeterminate thyroid FNAs.
MATERIALS AND METHODS

Case Selection
The study was approved by the institutional review board of the Johns Hopkins Hospital (JHH; IRB00124623). A retrospective search of the cytopathologic database at JHH was performed to identify consecutive thyroid FNAs diagnosed as AUS and tested with GEC from 2012 to 2016. The study population consisted of in-house patients who underwent FNA of a thyroid nodule at JHH and patients with outside FNA slides reviewed as part of a secondopinion confirming consultation. For in-house patients, an onsite evaluation was routinely performed by either an experienced cytotechnologist or an attending cytopathologist. Additional specimens were reserved for GEC testing if there was any suspicion on site of an indeterminate diagnosis. The GEC was used as a reflex test after a final diagnosis of either AUS or suspicious for a follicular neoplasm. Repeated FNA cases after an indeterminate diagnosis were rare during the study period and were excluded. For confirming cases, the outside FNA slides were reviewed together with the GEC results. The diagnostic criteria for AUS subcategories have been previously published. 9 In short, AUS-N indicates the presence of focal nuclear atypia, including nuclear enlargement, rare pseudo-inclusions, nuclear grooves, nuclear overlap, and nuclear elongation. Although present, the atypia is not sufficiently developed to support classification as suspicious for a papillary carcinoma (Fig. 1A,B) . AUS-F indicates the presence of focal microfollicular features that are insufficient for the diagnosis of suspicious for a follicular neoplasm (Fig. 1C) . Atypia of undetermined significance with nuclear atypia and a microfollicular pattern (AUS-N/F) is used when focal nuclear atypia and focal microfollicular features are both conspicuous. AUS-H indicates scant but disproportionately represented H€ urthle cells that are insufficient for the diagnosis of suspicious for a H€ urthle neoplasm. AUS-NOS is used to indicate the presence of atypical features that cannot be further designated into any of the aforementioned subcategories. A search of the surgical pathology database was performed for correlation with the histopathologic findings and to establish the final histopathologic diagnosis.
Reclassification of NIFTP
We retrieved all histopathologic slides of cases previously diagnosed as FVPTC on resection specimens. Slides were separately reviewed by 2 pathologists (J-F.H. and W.H.W.) to reclassify noninvasive FVPTC without worrisome histologic features as NIFTP on the basis of the new consensus criteria. 25 Cases showing any well-formed papilla were excluded for NIFTP. 31 Cases without initial agreement were shown at a multihead microscope to generate a consensus diagnosis. Subcentimeter nodules showing morphologic features consistent with NIFTP were still classified as such despite the size criterion.
31,32
Statistical Analysis
Descriptive statistics were determined to summarize data. Means and ranges were used for continuous variables, whereas counts and frequencies were used for categorical variables. An analysis of variance was performed to test differences between means of multiple groups. Fisher's exact tests were performed to compare proportions of categorical variables. McNemar's tests were used to examine changes in outcomes between matched pairs of subjects. Binary logistic regression models were used to estimate the odds ratios for outcomes related to a set of explanatory variables between 2 groups. Binomial proportion confidence intervals covering the true proportion 95% of the time were reported. Two-sided P values < .05 were considered to be statistically significant. Statistical analyses were performed with R software (version 3.2.2; R Foundation, Vienna, Austria) and Stata software (release 12; StataCorp, College Station, Texas).
RESULTS
Characteristics of the Study Cohort
Eight of 122 confirming-consultation FNAs (7%) were reclassified from AUS to either a benign diagnosis (n 5 7) or a diagnosis of suspicious for a follicular neoplasm (n 5 1), and they were excluded from this study. A total of 420 patients with 426 AUS nodules (312 nodules from the JHH in-house thyroid biopsy service and 114 from confirming consultations) were identified. Among them, 241 patients with 244 nodules had undergone thyroidectomy. The number of nodules in each AUS subcategory was as follows: 201 (47%) for AUS-N, 102 (24%) for AUS-F, 39 (9%) for AUS-N/F, 51 (12%) for AUS-H, and 33 (8%) for AUS-NOS. The number of nodules undergoing thyroidectomy in each AUS subcategory was as follows: 120 (49%) for AUS-N, 49 (20%) for AUS-F, 22 (9%) for AUS-N/F, 35 (14%) for AUS-H, and 18 (7%) for AUS-NOS. Figure 2 shows the distribution of the AUS subcategories. Among the patients who had undergone thyroidectomy, there were 59 men and 182 women with a mean age of 52 years (range, 17-90 years). The mean nodule size was 2.3 cm (range, 0.5-8.0 cm). Two hundred thirteen nodules (87%) had a suspicious GEC result. The demographic and pathologic findings are summarized in Table 1 .
Rates of Suspicious GEC Results in AUS Subcategories
Given that the majority of patients visiting for a second opinion and a confirmatory slide review had an AUS Figure 2 . Distribution of AUS subcategories in all nodules and in nodules undergoing thyroidectomy. AUS indicates atypia of undetermined significance; AUS-F, atypia of undetermined significance with a microfollicular pattern; AUS-H, atypia of undetermined significance with H€ urthle cells; AUS-N, atypia of undetermined significance with nuclear atypia; AUS-N/F, atypia of undetermined significance with nuclear atypia and a microfollicular pattern; AUS-NOS, atypia of undetermined significance, not otherwise specified.
nodule with a suspicious GEC result, we describe here the data only from the in-house biopsy patients, who better represent the general population. The rate of suspicious GEC results in each AUS subcategory from the JHH biopsy service was as follows: 48% (68 of 141) for AUS-N, 39% (30 of 76) for AUS-F, 34% (10 of 29) for AUS-N/F, 67% (24 of 36) for AUS-H, and 63% (19 of 30) for AUS-NOS. AUS-H had the highest rate of suspicious GEC results among all subcategories. There was no statistical significance in the rates of suspicious GEC results between AUS-N and AUS-F (P 5 .253), AUS-N and AUS-N/F (P 5 .221), and AUS-F and AUS-N/F (P 5 .823).
Reclassification of NIFTP and CytologicHistologic Correlation
Pathologic slides of all 48 tumors originally diagnosed as FVPTC were retrieved for review. After the review, 33 (69%) were reclassified as NIFTP. Three tumors were less than 1 cm (range, 0.6-0.7 cm). On the basis of the gross descriptions, all the tumors had been entirely submitted for histologic evaluation except for 2 large tumors (4.8 and 5.0 cm), for which the entire capsule had been submitted. As for the other 15 tumors originally diagnosed as FVPTC, 9 showed evidence of invasive growth, 4 showed a noninvasive FVPTC with more than 30% solid growth, 1 was reclassified as a classic papillary carcinoma, and 1 was reclassified as a follicular adenoma with reactive atypia.
The cytologic-histologic correlation in the AUS subcategories and the GEC results are summarized in Table 2 . NIFTP was considered nonmalignant in our analysis. A false-negative GEC result was noted in only 1 case: a follicular carcinoma that was diagnosed by FNA as AUS-N/F. All of the other resected NIFTPs were classified as suspicious by the GEC.
Impact of NIFTP on ROM for AUS Subcategories
Relevant correlations for the resected AUS nodules are summarized in Table 3 . The overall rate of suspicious GEC results was high (87%; range, 77%-94%). AUS-N and AUS-F had the highest correlation with the final diagnosis of NIFTP (18%), and they were followed by AUS-N/F (9%), AUS-H (3%), and AUS-NOS (0%). After we had accounted for the nonmalignant diagnosis of NIFTP, the ROM based on histologic follow-up and the entire cohort (unresected nodules were counted as benign) significantly decreased for AUS-N (P < .001) and AUS-F (P 5 .008). The change was not significant in the other AUS subcategories.
Comparison of ROM Between AUS Subcategories
To evaluate the differences in the ROM for AUS subcategories focusing on nuclear atypia and a microfollicular pattern, we used binary logistic regression models for univariate and multivariate analyses that were adjusted for age, sex, nodule size, and GEC results ( Table 4) . The ROM for AUS-N was significantly higher than that for AUS-F in the univariate analysis (P 5 .030) but not in the multivariate analysis (P 5 .089). The ROM for AUS with any nuclear atypia (AUS-N plus AUS-N/F) was significantly higher than that for AUS-F in both the univariate (P 5 .018) and multivariate analyses (P 5 .049).
DISCUSSION
AUS has been a useful, albeit problematic diagnostic category since it was first introduced by TBSRTC in 2010. FNAs could be placed into this category for different cytologic characteristics ranging from limited nuclear atypia Abbreviations: AUS, atypia of undetermined significance; AUS-F, atypia of undetermined significance with a microfollicular pattern; AUS-H, atypia of undetermined significance with H€ urthle cells; AUS-N, atypia of undetermined significance with nuclear atypia; AUS-N/F, atypia of undetermined significance with nuclear atypia and a microfollicular pattern; AUS-NOS, atypia of undetermined significance, not otherwise specified; GEC, gene expression classifier and focal architectural changes to H€ urthle cells or even atypical lymphocytic aspirates. 1 By subcategorizing AUS according to types of atypia, several studies have demonstrated differences in the ROM for better risk stratification. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] This approach has been adopted and is recommended by the new 2017 TBSRTC. 23 Two recent developments, namely, the application of molecular testing to indeterminate thyroid FNA nodules and the introduction of NIFTP as a nonmalignant diagnostic category, are likely to have a significant impact on the ROM, but this impact has not been adequately evaluated across the subcategories of AUS. In the current study, using tumor classification schemes that now include NIFTP, we changed the diagnosis from malignant to nonmalignant for 33 of the 48 (17) 1 (2) 6 (35) 1 (3) 2 (12) 28 (13) FVPTC, infiltrative 7 (7) 1 (2) 1 (6) 
Benign diagnosis 11 (100) 7 (100) 4 (80) 3 (100) 1 (100) 26 (96) Nodular hyperplasia/adenomatoid nodule 6 (55) 1 (14) 4 (80) 1 (33) 1 (100) 13 ( Abbreviations: AUS, atypia of undetermined significance; AUS-F, atypia of undetermined significance with a microfollicular pattern; AUS-H, atypia of undetermined significance with H€ urthle cells; AUS-N, atypia of undetermined significance with nuclear atypia; AUS-N/F, atypia of undetermined significance with nuclear atypia and a microfollicular pattern; AUS-NOS, atypia of undetermined significance, not otherwise specified; GEC, gene expression classifier; NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; ROM, rate of malignancy. a McNemar's tests were used to examine changes in malignancy between matched pairs. Bold type indicates statistical significance.
resected AUS nodules (69%) originally diagnosed as FVPTC. NIFTP was most commonly associated with an FNA diagnosis of AUS-N or AUS-F (18%), was less frequently associated with AUS-N/F (9%) and AUS-H (3%), and was not associated with AUS-NOS. By reclassifying NIFTP, we found that the ROM based on the histologic follow-up significantly decreased for the AUS-N (from 43% to 26%; P < .001) and AUS-F subcategories (from 29% to 10%; P 5 .008) but not for other subcategories of AUS. AUS-N still harbored a substantially higher ROM than AUS-F in the univariate analysis (P 5 .030). Given that the ROM based only on histologic follow-up may overestimate the true risk of malignancy, we also provided the ROMs based on the entire cohort ( Table 3) . The unresected nodules were regarded as benign for the calculation. The actual risk of malignancy is expected to between these 2 values.
To the best of our knowledge, only 3 recent studies on AUS subcategories considered the reclassification of NIFTP. Baca et al 17 reported a series of 100 AUS nodules with GEC results and histologic follow-up. Among them, AUS-N accounted for 25%, AUS-F accounted for 36%, and AUS-N/F accounted for 39% of the nodules. NIFTP was noted in 20% of AUS-N nodules, in 3% of AUS-F nodules, and in 23% of AUS-N/F nodules. When NIFTP was considered nonmalignant, there was no significant difference in the ROMs for AUS-N and AUS-F (20% vs 14%; P 5 .727). When we compare their results with the current study, we find that the diagnostic rate of each AUS subcategory was very different. AUS-N/F was the most frequent AUS subcategory in their series. In contrast, we tended to diagnose either AUS-N or AUS-F and limited an AUS-N/F diagnosis to rare cases showing equally prominent nuclear atypia and microfollicular features. The different diagnostic approaches to AUS subcategories might explain the differences in the rates of NIFTP and the ROMs between these 2 studies. As shown in Table 4 , we demonstrated that after NIFTP was considered nonmalignant, the ROM for AUS with any nuclear atypia (AUS-N plus AUS-N/F) was significantly higher than that for AUS with a microfollicular pattern only (AUS-F) in both univariate (P 5 .018) and multivariate analyses (P 5 .049). This result suggests that nuclear atypia is a more significant feature than a microfollicular pattern for subcategorizing AUS, despite the reclassification of NIFTP. In another study, Valderrabano et al 21 reported 127 resected AUS nodules, of which 42 (33%) showed nuclear atypia, 62 (49%) showed architectural atypia, 19 (15%) showed H€ urthle cell atypia, and 4 (3%) showed other types of atypia according to a retrospective review. No cases were classified with mixed nuclear and architectural atypia. After NIFTP was considered nonmalignant, the ROM for cases with nuclear atypia was higher than the ROM for cases with architectural atypia (19% vs 3%; P 5 .06). This study, along with ours, supports the idea of not overusing the AUS-N/F subcategory for better risk stratification in the current tumor classification schemes considering NIFTP. Gan et al 18 from the National University Hospital in
Singapore reported a series of 137 AUS nodules undergoing thyroidectomy. There were 37 malignant nodules, and 6 of them were FVPTC (5 as AUS-N and 1 as AUS-F). None of the 6 tumors fulfilled the diagnostic criteria of NIFTP after histologic review. A recent report showed low rates of encapsulated FVPTC and NIFTP among Asian countries (1.8% and 0.8%, respectively) 33 versus Western countries (24% and 18.6%, respectively). 25 These striking differences could be attributed to ethnic factors and different diagnostic criteria between these 2 regions. Therefore, the result of the current study may not be applicable to thyroid cytopathology practice in Asia. The Afirma GEC has been routinely used as a reflex test in conjunction with an onsite evaluation at our hospital since 2012. Comparing the current study with our previous study from 2009 to 2011 (before this change in practice), 9 we find that the distributions of AUS-N (49% vs 47%) and AUS-F (20% vs 23%) were about the same in these 2 cohorts. This suggests a high diagnostic consistency for AUS subcategories at our hospital. However, the ROM (NIFTP not excluded) before and after the application of the GEC was not significantly altered for AUS-N (48% vs 43%; P 5 .533) and AUS-F (27% vs 29%; P51.000). In the validation study, the GEC was demonstrated to have a high negative predictive value of 95%, which supported using the GEC as a rule-out test for AUS nodules. 34 Nonetheless, the change in practice from repeat FNA to an onsite evaluation and GEC testing for AUS nodules did not increase the overall ROM for excisional specimens by ruling out more benign nodules for surgery. Because 32% of AUS nodules were downgraded to a benign diagnosis by repeat FNA at our hospital, 9 to offer the choice of repeat FNA and to apply GEC only with a second AUS result might be a better strategy for preventing more unnecessary surgeries than reflex GEC testing on the first AUS FNA. Although NIFTP is regarded as a nonmalignant tumor with very low risk, it is still a surgical disease that, similarly to other follicular neoplasms, requires a complete examination of the tumor capsule to exclude capsular or vascular invasion. 35 Because of the change in practice, the utility of GEC testing in AUS nodules may require further evaluation. In summary, we have reported our 4-year experience with AUS subcategories at a tertiary care center that regularly performed onsite evaluations and GEC testing. More than two-thirds of the cases were subcategorized as either AUS-N or AUS-F, and only limited cases (9%) were interpreted as AUS-N/F. With this approach, NIFTP was most commonly associated with AUS-N and AUS-F diagnoses. Accordingly, the ROM after NIFTP was considered nonmalignant significantly decreased for AUS-N (from 43% to 26%; P < .001) and AUS-F (from 29% to 10%; P 5 .008). AUS-N still harbors a substantially higher ROM than AUS-F (P 5 .030).
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